COMP <GO>
RNAZ vs RMTI // EV/EBITDA & P/E VALUATION
TransCode Therapeutics Inc. (NASDAQ) VS. Rockwell Medical Inc. (NASDAQ) • 15-METRIC TALLY: RNAZ 0
— RMTI 4
■ METRIC PARITY
LAST: $1.73 (-0.57%) • MKT CAP: $29.3M
valuation
—
LAST: $7.31 (0.00%) • MKT CAP: $29.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RNAZ VS. RMTI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RNAZ | RMTI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 16.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -10.60% | -24.40 | RMTI | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -2.24% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -6.80% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -7.70% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | RMTI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.8 | 41.0 | -0.18 | RMTI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.3M | $29.5M | -$172.5K | RMTI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RNAZ REV | RMTI REV | RNAZ GROSS % | RMTI GROSS % | RNAZ FCF | RMTI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $69.3M | — | 16.9% | -$19.5M | -$659.0K |
| FY 2024 | $0 | $101.5M | — | 17.2% | -$13.4M | $4.2M |
| FY 2023 | $0 | $0 | — | — | -$18.1M | -$9.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RNAZ // BETA —
RMTI // BETA —